Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, efficacy (including quality of life), and
pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with
unresectable and/or metastatic renal cell cancer, who have received one prior systemic
regimen for advanced disease.